Similar to what we found in our own study (11), at 10–12 days after a second COVID vaccine, there was no difference in the frequencies of activation-induced marker–positive (AIM+) TCM-phenotype cells but CD8+ T cells were increased for the terminally differentiated TEM- and TEMRA-phenotype cells in patients with MS receiving anti-CD20 therapy (Figure 5, F and G). The gene discussed is CD8A; the disease is myeloid sarcoma.